Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

NCT02440685 is registered in ClinicalTrials.gov with Asana BioSciences as lead sponsor.

NCT NCT02440685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02440685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Lead sponsor
Asana BioSciences
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2015
Completion date
July 31, 2018
Enrollment
51 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, b-cell leukemia, chronic, b-lymphocytic leukemia, chronic, cancer, chronic idiopathic myelofibrosis, chronic lymphocytic leukemia, idiopathic myelofibrosis, leukemia, lymphocytic, chronic, leukemia, lymphocytic, chronic, b cell, lymphoma, b-cell, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, malignant, lymphoma, mantle-cell, lymphoma, non-hodgkin, lymphoma, t cell, peripheral, myelofibrosis, neoplasm, peripheral t-cell lymphoma, t-cell lymphoma, peripheral, tumor